Tags » Outcomes Research

IMPROVE-IT becomes the first trial to prove the “LDL Hypothesis” with a non-statin drug

The highly anticipated trial results have reaffirmed the “LDL hypothesis” and offer a particularly positive outlook for present and future LDL cholesterol-lowering medications.

Merck’s Vytorin can IMPROVE-IT… 650 more words

Outcomes & Research

See you at ISPOR Amsterdam next week. IHS booth 809!

The IHS Life Sciences team is pleased to announce that we will have a strong presence at the ISPOR 17th European Congress in Amsterdam, 8-12 November 2014. 363 more words

Outcomes & Research